Shockwave Medical Inc
F:36M
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Shockwave Medical Inc
F:36M
|
11.3B EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
132.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
115.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.8B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Shockwave Medical Inc
Glance View
Shockwave Medical Inc. has established itself as a significant player in the healthcare sector thanks to its innovative approach to tackling calcified cardiovascular disease. Founded with the vision of addressing the inefficiencies and limitations of traditional treatment methods, the company has embarked on a path that fuses medical expertise with cutting-edge technology. The core of Shockwave's operation lies in its proprietary intravascular lithotripsy (IVL) technology, which employs sonic pressure waves to safely and effectively fracture problematic calcium deposits in the arteries. This approach not only enhances the safety profile compared to other invasive procedures but also improves the outcomes for patients enduring complex calcified lesions, a common hurdle in cardiovascular treatments. It's through the pioneering use of this technology that Shockwave Medical generates its revenue. The company's product portfolio, which includes devices like the Shockwave M5 and Shockwave C2 catheters, is designed to cater to a wide spectrum of calcified cardiovascular issues. By selling these devices directly to hospitals and healthcare providers across the globe and supporting them with robust clinical data showing improved patient outcomes, Shockwave has cemented its place in the medical device industry. Furthermore, its business model benefits from recurring revenues as healthcare providers continually purchase these specialized devices for ongoing procedures. This consistent demand underscores the company's balanced approach to innovation and profitability in a market primed for technological advancements.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Shockwave Medical Inc is 87%, which is above its 3-year median of 86.9%.
Over the last 3 years, Shockwave Medical Inc’s Gross Margin has increased from 72.4% to 87%. During this period, it reached a low of 72.4% on Mar 3, 2021 and a high of 87% on May 1, 2024.